US 12,134,659 B2
Anti-human MASP-2 antibody, preparation method therefor and application thereof
Yipan Wu, Shanghai (CN); Wei Dang, Shanghai (CN); Chenghai Zhang, Shanghai (CN); Lingqiao Zhu, Shanghai (CN); Jinlin Guo, Shanghai (CN); Yujing Yuan, Shanghai (CN); Qiuling Zou, Shanghai (CN); Yang Wang, Shanghai (CN); and Shun Hu, Shanghai (CN)
Assigned to SHANGHAI MABGEEK BIOTECH. CO., LTD., Shanghai (CN)
Filed by SHANGHAI MABGEEK BIOTECH. CO., LTD., Shanghai (CN)
Filed on Oct. 13, 2023, as Appl. No. 18/486,644.
Application 18/486,644 is a continuation of application No. PCT/CN2022/079499, filed on Mar. 7, 2022.
Claims priority of application No. 202110404540.6 (CN), filed on Apr. 15, 2021.
Prior Publication US 2024/0043563 A1, Feb. 8, 2024
Int. Cl. C07K 16/40 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. An antibody specifically binding to human MASP-2 or an antigen-binding fragment thereof, comprising a heavy chain variable region, wherein the heavy chain variable region comprises an HCDR3 sequence, an HCDR2 sequence and an HCDR1 sequence, wherein the HCDR3 sequence comprises an amino acid sequence as shown in SEQ IDS NO: 47; and, the HCDR2 sequence comprises an amino acid sequence as shown in SEQ ID NO: 46; and, the HCDR1 sequence comprises an amino acid sequence as shown in SEQ ID NO: 45;
and, the antibody or the antigen-binding fragment thereof further comprising a light chain variable region, wherein the light chain variable region comprises an LCDR1 sequence, an LCDR2 sequence, and an LCDR3 sequence, wherein the LCDR3 sequence comprises an amino acid sequence as shown in SEQ ID NO: 50; and, the LCDR2 sequence comprises an amino acid sequence as shown in SEQ ID NO: 49; and, the LCDR1 sequence comprises an amino acid sequence as shown in SEQ ID NO: 48.